Diabetes Board decisions

The Board denied service connection for a left meniscus tear, right knee instability, chronic sinusitis or other condition of the nose, throat, larynx and pharynx, diabetes, type 1 or type 2, hypertension (high blood pressure), tinnitus, and visual impairment, including blurry vision, blindness and double vision.

The Board granted service connection for diabetes mellitus, type II, a heart condition, and hypertension as secondary to the Veteran's service-connected acquired psychiatric disorder.

The Board remands all claims for service connection to the AOJ for further development, including obtaining relevant VA and private medical records and scheduling a VA examination.

The Board granted service connection for diabetes mellitus type II, as secondary to the Veteran's service-connected hepatitis C with cirrhosis of the liver.

The appeal for entitlement to a total disability rating based on individual unemployability (TDIU) is dismissed as moot due to the Veteran's 100 percent combined rating assigned for his service-connected disabilities.

The Board remands the matter for a duty-to-assist error in failing to obtain a toxic exposure risk activity (TERA) opinion.

The appeal was dismissed due to the Veteran's death during its pendency.

The Board granted service connection for allergic rhinitis and remanded the other claims for further development.

The Board remands the claims for service connection for type II diabetes and bilateral leg scarring for further development, including obtaining medical opinions on whether the conditions are secondary to service-connected hypertension.

The Board denied the Veteran's claim for special monthly compensation (SMC) based on aid and attendance, as her need for assistance is not solely due to service-connected disabilities.

The Board denied service connection for right knee, left knee, diabetes, left finger, and acquired psychiatric disorder due to the lack of new and relevant evidence. The claims for sleep apnea and headaches were remanded for further development.

The Board remands the claims for service connection for colon cancer, hypertension, diabetes mellitus, vision condition (secondary to diabetes mellitus), erectile dysfunction, headaches, and peripheral neuropathy of the left foot/heel due to a need for additional development, including VA examinations.

The Board granted an effective date of April 22, 2022, for the award of entitlement to service connection for mild non-proliferative diabetic retinopathy and denied earlier effective dates for total disability rating based on individual unemployability (TDIU) and eligibility for Dependents' Educational Assistance under 38 U.S.C. Chapter 35.

The Veteran was granted a 10 percent rating for his right eye disability effective February 22, 2022.

The Veteran is granted a separate rating of 20 percent for benign prostatic hyperplasia (BPH) and denied an increased rating for diabetic nephropathy. The effective date for the service connection awards is August 26, 2023.

The Board granted service connection for diabetes mellitus Type II, hypertension, bilateral femoral stents for peripheral vascular disease (PVD), and heart disability, but denied service connection for Parkinson's disease.

The Board remands the case to obtain new medical opinions regarding the Veteran's cause of death, specifically addressing his service in the Panama Canal Zone and potential exposure to toxins.

The Board granted service connection for diabetes mellitus type II, hypertension as secondary to diabetes mellitus type II, and bilateral lower extremity diabetic peripheral neuropathy as secondary to diabetes mellitus type II.

The Board granted service connection for diabetes mellitus type 2 and remanded the claims for a back condition, peripheral artery disease, pes planus, and right foot or toe condition.

The Board granted service connection for depressive disorder with anxiety disorder and bilateral lower extremity diabetic neuropathy, atherosclerotic cardiovascular disease, and chronic kidney disease, all secondary to diabetes mellitus. A 30 percent initial rating was granted for stasis dermatitis.